景泽生物：一年亏2.4亿，资产负债率486%闯关港交所

和讯网2025-07-10

快讯摘要6月27日景泽生物赴港递表，近2年亏4.89亿，负债率486.5%，产品竞争激烈，上市成败关乎生死快讯正文【景泽生物赴港递表，生存危机下上市征程充满未知】 6月27日，景泽生物科技有限公司向港交所主板递交招股书，中金公司（601995）、国元国际为联席保荐人。该公司聚焦辅助生殖与眼科赛道，虽有三大后期管线，但面临无实质收入、持续亏损、竞争激烈和高资产负债率等危机。招股书显示，景泽生物在两...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550368621?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-10 22:28","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550368621","market":"hk","top_or_hot":-1,"title":"景泽生物：一年亏2.4亿，资产负债率486%闯关港交所","media":"和讯网","content":"<div>\n<p>快讯摘要6月27日景泽生物赴港递表，近2年亏4.89亿，负债率486.5%，产品竞争激烈，上市成败关乎生死快讯正文【景泽生物赴港递表，生存危机下上市征程充满未知】 6月27日，景泽生物科技有限公司向港交所主板递交招股书，中金公司（601995）、国元国际为联席保荐人。该公司聚焦辅助生殖与眼科赛道，虽有三大后期管线，但面临无实质收入、持续亏损、竞争激烈和高资产负债率等危机。 招股书显示，景泽生物在两...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710223223953d9075&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>景泽生物：一年亏2.4亿，资产负债率486%闯关港交所</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n景泽生物：一年亏2.4亿，资产负债率486%闯关港交所\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-10 22:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710223223953d9075&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>快讯摘要6月27日景泽生物赴港递表，近2年亏4.89亿，负债率486.5%，产品竞争激烈，上市成败关乎生死快讯正文【景泽生物赴港递表，生存危机下上市征程充满未知】 6月27日，景泽生物科技有限公司向港交所主板递交招股书，中金公司（601995）、国元国际为联席保荐人。该公司聚焦辅助生殖与眼科赛道，虽有三大后期管线，但面临无实质收入、持续亏损、竞争激烈和高资产负债率等危机。 招股书显示，景泽生物在两...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710223223953d9075&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0898667661.SGD","symbol_name":"JPMorgan Funds - Asia Pacific Income A (mth) SGD-H","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710223223953d9075&s=b","article_id":"2550368621","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710223223953d9075&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550368621","pubTimestamp":1752157683,"columns":[{"name":"港股","id":23,"label_key":"policyRegulatory"}],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"快讯摘要6月27日景泽生物赴港递表，近2年亏4.89亿，负债率486.5%，产品竞争激烈，上市成败关乎生死快讯正文 6月27日，景泽生物科技有限公司向港交所主板递交招股书，中金公司、国元国际为联席保荐人。此次赴港上市，资金将用于核心产品开发、临床试验等。辅助生殖市场潜力大，2024年不孕不育夫妇达5920万对，预计2030年增至约6840万对。截至2024年末，公司可赎回负债高达13.3亿元，资产负债率486%。综合来看，景泽生物上市征程未知。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"80388":"香港交易所-R","LU0898667661.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD-H","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU0261947096.USD":"FIDELITY FUNDS  SUSTAINABLE ASIA EQUITY \"A\" (USD) ACC","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0061477393.USD":"CT (LUX) I ASIA EQUITY INCOME \"AU\" (USD) ACC","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","SG9999001051.SGD":"United Asia Fund SGD","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1642822792.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"A\" (SGD) ACC","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU0831093199.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AM3\" (SGDHDG) INC","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU0630378429.USD":"HSBC GIF ASIA PACIFIC EX JAPAN EQ HD \"AM2\" (USD) INC","LU1282649810.SGD":"Allianz Asian Multi Income Plus Cl AMg DIS H2-SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0197773160.USD":"HSBC GIF ASIA PACIF EX JAPAN EQ HD \"AC\" ACC","LU0762542818.HKD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AM\" (HKD) INC","HKXCY":"香港交易所ADR","SGXZ90724238.SGD":"UNITED ASIA \"A\" (SGD) INC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0197773673.USD":"HSBC GIF ASIA PACIF EX JAPAN EQ HD \"AS\" (USD) INC","BK1589":"北水核心资产","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","SG9999001846.SGD":"Schroder Asian Equity Yield A Dis SGD","LU0831103253.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","BK1131":"金融交易所和数据","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1282648689.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AMG\" (USD) INC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0577902538.SGD":"Fullerton Lux Funds - Asia Growth and Income Equities A Acc SGD","LU1282649067.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AMG\" (USD) INC A","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0359201612.USD":"贝莱德中国基金A2","00388":"香港交易所","LU0594300419.USD":"富达中国消费基金A"},"translate_title":"Jingze Biotech: Loss 240 million a year, asset-liability ratio 486%, break through the Hong Kong Stock Exchange","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"80388":0.6,"HKXCY":0.6,"00388":0.9,"HEXmain":0.6},"content_text":"快讯摘要6月27日景泽生物赴港递表，近2年亏4.89亿，负债率486.5%，产品竞争激烈，上市成败关乎生死快讯正文【景泽生物赴港递表，生存危机下上市征程充满未知】 6月27日，景泽生物科技有限公司向港交所主板递交招股书，中金公司（601995）、国元国际为联席保荐人。该公司聚焦辅助生殖与眼科赛道，虽有三大后期管线，但面临无实质收入、持续亏损、竞争激烈和高资产负债率等危机。 招股书显示，景泽生物在两大赛道研发管线优势显著，八在研管线中三款核心产品进入后期开发。不过，近两年累计净亏损超4.89亿元，无商业化收入，2023 - 2024年净亏损分别为2.46亿、2.43亿元，研发费用高。 现金流方面，2023 - 2024年经营活动现金流净流出，截至2024年末现金及等价物仅剩6858.6万元，仅够维持五个月支出。此次赴港上市，资金将用于核心产品开发、临床试验等。 辅助生殖市场潜力大，2024年不孕不育夫妇达5920万对，预计2030年增至约6840万对。景泽生物JZB30为促排卵生物类似药，已获批上市，与安科生物（300009）合作推广，但市场竞争激烈。 眼科药物领域，JZB05处于III期临床，面临激烈竞争。国内已有两款阿柏西普类药物获批，另有两家企业同类药处于临床研究阶段。 市场对“me - too”药物估值偏好降温，或影响景泽生物估值。IPO前，景泽生物六轮融资获9.27亿元，投资者包括恒瑞医药（600276）相关机构，公司估值增至30.9亿元。 截至2024年末，公司可赎回负债高达13.3亿元，资产负债率486%。若未在2025年12月31日前上市，C + 轮投资者有权要求赎回股份。 综合来看，景泽生物上市征程未知。上市或缓解资金危机，失败则赎回负债将带来巨大压力。本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550368621","isCrawlerRequest":true}